Inhibikase Therapeutics (IKT) EBITDA (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of EBITDA data on file, last reported at -$17.8 million in Q1 2026.

• On a quarterly basis, EBITDA fell 22.22% year-over-year to -$17.8 million in Q1 2026; TTM through Mar 2026 was -$55.2 million, a 43.78% decrease from a year earlier, with the FY2025 full-year figure at -$52.0 million, down 81.8% from the prior year.
• EBITDA for Q1 2026 stood at -$17.8 million, down from -$13.8 million in the prior quarter.
• Over the last five years, EBITDA for IKT reached as high as -$4.3 million in Q4 2022 and fell as low as -$17.8 million in Q1 2026.
• Historically, EBITDA has averaged -$8.0 million across 5 years, with a median of -$5.1 million in 2024.
• Across the five-year window, EBITDA increased 18.57% in 2024 and plunged 205.25% in 2025, its largest moves.
• Year by year, EBITDA stood at -$4.3 million in 2022, then retreated by 1.58% to -$4.4 million in 2023, then slumped by 193.6% to -$12.9 million in 2024, then slipped by 6.55% to -$13.8 million in 2025, then decreased by 29.52% to -$17.8 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$17.8 million in Q1 2026, -$13.8 million in Q4 2025, and -$12.8 million in Q3 2025.